Industry landscapes
Get Pro
Industry report

Funding and advertised pay are reported in USD; filed accounts retain their stated source currency and basis.

Exchange-rate basis

Indicative conversions use ECB reference rates dated 2026-09-14, applied consistently across all periods. They are not historical exchange rates. Indian rupees may use crore (1 crore = 10 million); other currencies use K, M and B. CSV downloads, source documents and quoted news headlines retain their original currencies.

THE THE UNITED STATES EDITION 2026

the United States’s
cancer therapeutics industry,
in focus.

The companies, capital and talent shaping cancer therapeutics in the United States. Find the leaders. Understand the segments. See where the activity is.

Explore in Radar Read the key signals
Snapshot: Funding in USD
Illustrated cover for Cancer Therapeutics Industry Landscape of the United States
US
COMPANIES · CAPITAL · TALENT

An industry ecosystem,
measured in context.

Cancer Therapeutics illustration
Companies tracked 1,021Cancer Therapeutics ecosystem in the United States Disclosed funding $74.01B727 companies · all recorded rounds Companies hiring 98With open roles at the snapshot Tracked open roles 2710 employers posted in the preceding 30 days
MEET THE COMPANIES

Explore the United States’s cancer therapeutics leaders

24 featured companies from the funding, hiring, revenue and team-size leaderboards.

Expand panel +
Explore the full landscape
Cancer Therapeutics company highlights in the United States, snapshot 31 August 2026
Company
BeiGenebeigene.com$5.07B10 roles1,090$5.34BFYFY2025 filing
Celgenecelgene.com$3.08B—4,891—
Novavaxnovavax.com$2.73B—184Financial figure available in RadarView in Radar
Halozymehalozyme.com$1.29B—373$1.4BFYFY2025 filing
ImmunityBioimmunitybio.com$1.13B11 roles725—
Seattle Geneticsseagen.com$1.06B—2,404—
Candid Therapeuticscandidrx.com$875M———
Incyteincyte.com$750M—1,387$5.14BFYFY2025 filing
Dyne Therapeuticsdyne-tx.com—8 roles116—
SOFIEsofie.com—8 roles298—
Systimmunesystimmune.com—8 roles36—
Umoja Biopharmaumoja-biopharma.com—8 roles168—
Allogene Therapeuticsallogene.com—7 roles303—
Lantheuslantheus.com—7 roles834$1.54BFYFY2025 filing
ADMA Biologicsadmabiologics.com——498Financial figure available in RadarView in Radar
Arcus Biosciencesarcusbio.com——577$33MFYFY2025 filing
Artivaartivabio.com——15—
Atara Biotherapeuticsatarabio.com——909Financial figure available in RadarView in Radar
Dynavaxdynavax.com——408$277.25MFYFY2024 filing
FibroGenfibrogen.com——592$6.44MFYFY2025 filing
Inhibrxinhibrx.com——112—
Iovanceiovance.com——557—
Kyverna Therapeuticskyvernatx.com——96—
NantKwestnantkwest.com——641—
24 featured companies

Locked revenue figures are available in Radar; the eight company financial previews stay the same throughout this page. A dash means the figure is outside these featured lists. Revenue years vary by company; the figures are not a like-for-like revenue comparison. Compare annual accounts ↗

Company discovery

Recorded evidence only

Explore the live startup set in Radar

No company example met every recorded classification, independence and public-profile gate in this snapshot. The live directory may have newer qualifying companies.

Explore classified startups in Radar ↗
THE KEY SIGNALS

Cancer Therapeutics industry KPIs in the United States

A few useful ratios bring the size of this ecosystem into perspective.

31 August 2026
Hiring participation9.6%

98 of 1,021 tracked companies have open roles.

Funding participation73.1%

746 of 1,021 tracked companies have a recorded round.

Top 3 funding share14.7%

Share of disclosed capital received by the three largest recorded recipients.

Median disclosed round$5M

Midpoint of 1,773 rounds with a disclosed amount.

Scale is concentrated. Opportunity is broader. The three largest funding recipients hold 14.7% of disclosed capital, while 26.9% of tracked companies have no recorded funding round.

Explore the segments →
CAPITAL & COMPANY FORMATION

How the United States cancer therapeutics has grown

Recorded company formation and disclosed funding across the complete annual series shown.

Expand panel +
2016 — 2025

Disclosed funding by year

Sum of recorded funding rounds · USD

the United States cancer therapeutics
$0$3.23B$6.47B$9.7B$12.94B2016: $2.89B20162017: $5.39B20172018: $5.98B20182019: $6.84B20192020: $11.35B20202021: $7.12B20212022: $4.56B20222023: $4.56B20232024: $5.87B20242025: $4.09B2025
View the numbers
Annual cancer therapeutics funding and company formation in the United States
YearFunding (USD)FoundedRaising
2016$2.89B66140
2017$5.39B64125
2018$5.98B65134
2019$6.84B80126
2020$11.35B63163
2021$7.12B58153
2022$4.56B45133
2023$4.56B20140
2024$5.87B16125
2025$4.09B3138
WHERE CAPITAL SITS

Funding concentration

Share of all disclosed company funding.

  • BeiGene6.9%
  • Celgene4.2%
  • Novavax3.7%
  • Other companies85.3%

Funding by stage

1,893 recorded rounds since 2016

NUMBER OF ROUNDS
Seed & Angel250 13.2%
Series A–B564 29.8%
Series C+ / PE147 7.8%
Grants, debt & other932 49.2%

Recent recorded rounds

Latest recorded rounds · USD
8 rounds

Swipe or scroll horizontally to browse.

Largest and notable recorded rounds

Each card is one recorded round
10 cards

Swipe or scroll horizontally to browse.

THE BUSINESS BEHIND THE ACTIVITY

Revenue, profitability & financial strength

Annual accounts for reporting companies linked to this landscape, on like-for-like currency and reporting bases.

Expand panel +
USD · millions · consolidated

Display conversions use the dated reference rates above. Where a verified rate is unavailable, figures retain their source currency. Each reporting cohort keeps its currency and accounting basis separate.

FY2025 · annual statements grouped by reported fiscal year; exact entity periods remain on preview rows · 56 reporting entities from 144 eligible matches.

Revenue in covered accounts$18,225.2m

Sum of reporting-entity revenue; not the United States market sales.

Net profit / loss$-1,534.9m

Combined result for the same cohort.

Aggregate net margin-8.4%

Combined net income ÷ combined revenue.

Median company revenue$10.3m

The middle covered reporting entity.

Profitable entities+23.2%

13 of 56 covered entities.

Top-five concentration+79.8%

Share of covered revenue from the five largest entities.

Annual account trend

Reported cohort totals by year; coverage is stated for every period.

Bar height shows revenue. Changes in coverage can affect totals.

Profitability has two perspectives

FY2025 · 56 reporting entities

Open the company accounts

Up to eight fixed company previews show financial amounts. Search and sort the wider company list, then continue in Radar.

56 reporting entities
Continue your financial research in Radar

Explore full company accounts and filings.

View financials in Radar ↗
THE UNITED STATES · INDUSTRY COHORTS

How does cancer therapeutics compare?

Each pair uses the same year, currency and reporting basis. Cohort overlap is disclosed.

IndustryCovered / eligibleRevenue totalMedian revenueNet profit / lossAggregate marginProfitable shareOverlap

Available-account cohorts are not estimates of whole industries. Overlapping entities can occur in more than one cohort; do not add cohort totals.

Coverage, calculations & financial sources

Filed annual accounts for exact designated national identifiers. Every aggregate and peer pair uses one fiscal year, source currency and reporting basis; periods, coverage and overlap are explicit; 2026 partials are excluded.

The same up to eight reporting entities remain open across years, filters and sorts. Other company figures are available in Radar.

Source currencies and accounting bases stay separate. Missing accounts are excluded rather than treated as zero. Exact reporting periods appear on company previews. Annual totals can change with coverage and do not measure growth of a fixed company cohort.

INSIDE THE INDUSTRY

The the United States cancer therapeutics market map

Explore the segments behind the headline numbers.

Expand panel +

Where companies are building

Rank segments by scale, hiring or disclosed funding.

Life sciences1,018
Biopharmaceuticals908
Enterprise tech869
Medical devices96
Enterprise software73
Deep tech62
Consumer digital49
Neurodegenerative diseases drugs24
Nanomedicine18
Jlabs portfolio17
Healthtech17
Anti bacterial drugs16

Companies can sit in several segments. Counts and funding overlap.

SEGMENT TO EXPLORE

Life sciences

The largest measured segment in this report snapshot.

1018companies
9.6%have hiring activity

98 companies hiring · $73.96B disclosed funding

Explore in Radar

How companies make money

Common revenue models; a company can use more than one.

Physical commerce598
E-commerce - product293
Fee-for-service274
Subscription179
Commission on transaction17
Advertising12
E-commerce - service2
Licensing1
THE COMPANIES IN MOTION

Who is listing, hiring leaders, launching and winning work

Recorded corporate activity linked to companies in this landscape.

Expand panel +
Recent corporate headlines 10 dated reports
Mergers & acquisitionscandidrx.com ↗

UCB SA agreed to pay $2 billion up front to acquire bispecific T-cell engager (TCE)-maker Candid Therapeutics Inc. and lead BCMA/CD3 TCE asset cizutamig (CND-106), continuing big pharma’s spree for China-made autoimmune assets in 2026.

Funding roundscabalettabio.com ↗

Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA ), a clinical-stage biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced today the pricing of an underwritten offering of 51,725,000 shares of common stock. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $150 million.

Mergers & acquisitionsajaxtherapeutics.com ↗

Eli Lilly and Company (NYSE: LLY) has agreed to acquire Ajax Therapeutics, Inc. in a cash deal worth up to $2.3 billion, including upfront and milestone-linked payments, to add a first-in-class Type II JAK2 inhibitor to its expanding oncology pipeline.

Mergers & acquisitionssmmttx.com ↗

Manchester-headquartered agency Glass Atlas has acquired Summit, including its proprietary Productcaster platform.

Mergers & acquisitionskeloniatx.com ↗

Eli Lilly has entered a definitive agreement to acquire Kelonia Therapeutics for up to $7 billion.

Mergers & acquisitionsobsidiantx.com ↗

RTW Biotech Opportunities Ltd, a London-listed investment company focused on the life sciences sector, said Tuesday that portfolio company Obsidian Therapeutics Inc. has agreed to merge with Galera Therapeutics Inc. in a reverse merger that includes a $350 million private placement.

Funding roundsallogene.com ↗

Allogene Therapeutics, Inc. (Nasdaq: ALLO ) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $175 million of shares of its common stock.

Funding roundsimmunitybio.com ↗

ImmunityBio announced $100 million of financing transactions, including $75 million of non‑dilutive financing under its Royalty Interest Purchase Agreement (RIPA), which strengthens the balance sheet to support global expansion and pipeline work.

Funding roundsrybodyn.com ↗

SeaX Ventures, a venture capital firm focusing on Southeast Asia, will continue investing in RyboDyn, a biotechnology startup based in the United States, as part of the latter’s $10 million seed funding round.

Funding roundsimmunebridge.com ↗

The San Francisco biotech announced a second seed round of $7.7 million USD, led by NFX – the venture firm behind Lyft, DoorDash, and Mammoth Biosciences, with over $1.5 billion USD under management – alongside One Way Ventures, M Ventures, Insight Partners, LongGame Ventures, T.Rx Capital, Healthspan Capital, Sand Hill Angels, and two independent investors.

Full recorded event mix

Top 10 categories among 3,013 recorded events in the 24-month window.

Earnings
768
Funding rounds
509
Leadership moves
484
Mergers & acquisitions
266
IPO activity
261
Company announcements
162
Lawsuit
133
Contracts
120
Regulatory
72
Asset acquisitions
61
6 activity cards

Swipe or scroll horizontally to browse.

IPO pipeline

85 companies with recorded IPO activity

Follow-on Offering · NASDAQ1 reports

Follow-on Offering · Nasdaq1 reports

Follow-on Offering · NYSE American2 reports

OFS · NASDAQ1 reports

GeoVax ↗

Direct Listing · Nasdaq1 reports

IPO activity · NASDAQ1 reports

Follow-on Offering · Nasdaq1 reports

OFS · Nasdaq5 reports

Leadership moves

114 tracked people moves

AlloVir ↗
Shawn Cline Tomasello, MBA

Departure Previously Board Member

Incyte ↗
Suketu Upadhyay

Appointment Executive Vice President and Chief Financial Officer

Shawn Cline Tomasello, MBA

Departure Previously Board Member

CoRegen ↗
Shawn Cline Tomasello, MBA

Departure Previously Board Member

Incyte ↗
Pablo Cagnoni

Appointment President and Global Head of Research and Development

Howard Berman, Ph.D.

Resignation Previously Executive Chairman

Mark H. Pavao

Appointment Independent Director

Onconetix ↗
Sammy Dorf

Appointment Member of the Board of Directors

Contract wins

66 recorded customer wins

Incyte ↗

Customer: Buccini Pollin GroupReal Estate

Novavax ↗

Customer: pfizerbiopharmaceutical

AbelZeta ↗

Customer: astrazeneca

Halozyme ↗

Customer: takeda

Novavax ↗

Customer: Takeda PharmaceuticalHealthcare

Dren Bio ↗

Customer: sanofiPharmaceuticals

Regulatory events

87 recorded events

ImmunityBio ↗

requested additional information for resubmissionFDA

ImmunityBio ↗

approved for BCG-unresponsive NMIBCFDA

ImmunityBio ↗

conditional marketing authorization grantedEuropean Commission

ImmunityBio ↗

authorization grantedMHRA

Litigation

29 tracked suits

Company
tesaro v anaptysbio

Anticipatory breach and declaratory judgment dispute over license agreementCivil · Ongoing

Company
ImmunityBio investors v immunitybio

securities fraudClass Action · Filed

Earnings pulse

Reported company results in the recorded window.

130companies
915period observations
22.8%median reported growth

Median across 213 reported growth observations; companies may contribute multiple periods.

Mergers and acquisitions

Company-linked deal reports; status is preserved as recorded.

Acquirer → targetStatusDateValue / context
merck sharp & dohme→Artiva ↗Terminated2026-06-25$1.9B
UCB SA→Candid Therapeutics ↗Announced2026-05-04$2.0B
Candid Therapeutics→rallybioTerminated2026-05-04Not stated in snapshot
Glass Atlas→Summit ↗Announced2026-04-29Not stated in snapshot
eli lilly→Ajax ↗Announced2026-04-28$2.3B
eli lilly→Kelonia ↗Completed2026-04-28$7.0B

A discussion or rumour is not a completed transaction. An unstated value is not zero.

PEOPLE & OPPORTUNITY

The talent market

1,848 postings in the preceding 12 months. The full 2,275-posting snapshot covers 94 employers.

Expand panel +

Most advertised job titles

Registered Nurse11
Direct Support Associate10
Director, Digital Marketing, Market Access Strategic Marketing9
Qc/Production Associate I9
Marketing Manager, Ecommerce Amazon8
Pharmacy Technician I8
0 internship postings

26 tracked postings mention remote work.

The seniority mix

1,297 postings specify a level.

unspecified
978
manager
753
senior
450
lead
55
intern
37
entry
2

Skills employers mention

Top skills across 2,275 tracked postings in the available jobs snapshot.

Excel
35
Word
20
Gmp
20
Python
17
Data Analysis
16
Gcp
15
Powerpoint
15
Microsoft Office
14
Cgmp
14
Project Management
12
ADVERTISED PAY$132.0K/ year

Median across 307 postings with pay data, expressed in USD.

Salary by seniority

manager$170.0K/ year122 postings
senior$144.1K/ year78 postings

Advertised posting medians do not describe all employees or roles.

THE PEOPLE BUILDING THE FIELD

Founders and leaders

874 founders and chief executives across 601 companies.

Expand panel +
12 profiles

Swipe or scroll horizontally to browse.

Education networks

212 profiles with education records.

Stanford University
42
Harvard University
40
Massachusetts Institute of Technology
26
University of Pennsylvania
18
University of California (Berkeley)
14
Cornell University
12
Harvard Business School
12
University of Cambridge
12

Prior employers

14 profiles with prior-work records.

McKinsey
7
Google
2
Boston Consulting Group
2
Microsoft
2
Morgan Stanley
1

Profiles cover recorded founders and leaders; contact details remain in Radar.

NEWS INTELLIGENCE

How this industry appears in the news

247,166 articles in the measured 12-month window.

Expand panel +
247,166articles in the measured year
60,349articles in 2026Q1
64.0%positive tone in the latest complete year

News volume trends

Cancer Therapeutics coverage across United States · articles per complete quarter

035,87871,756107,634143,5122021Q2: 115,4872021Q22021Q3: 113,6252021Q4: 91,4562022Q1: 87,4752022Q2: 63,6462022Q22022Q3: 58,5072022Q4: 59,9872023Q1: 59,4482023Q2: 68,0542023Q22023Q3: 54,4022023Q4: 59,2852024Q1: 64,4522024Q2: 63,3352024Q22024Q3: 57,3222024Q4: 57,0552025Q1: 124,7932025Q2: 53,9812025Q22025Q3: 77,9482025Q4: 55,2732026Q1: 60,3492026Q1
View quarterly article counts
QuarterArticles
2021Q2115,487
2021Q3113,625
2021Q491,456
2022Q187,475
2022Q263,646
2022Q358,507
2022Q459,987
2023Q159,448
2023Q268,054
2023Q354,402
2023Q459,285
2024Q164,452
2024Q263,335
2024Q357,322
2024Q457,055
2025Q1124,793
2025Q253,981
2025Q377,948
2025Q455,273
2026Q160,349

Article volume measures coverage, not market sales.

Tone of coverage over time

2021
172,132 positive · 3,763 neutral · 172,918 negative
2022
160,520 positive · 3,593 neutral · 105,042 negative
2023
172,129 positive · 3,287 neutral · 65,357 negative
2024
173,318 positive · 3,192 neutral · 65,170 negative
2025
199,318 positive · 3,876 neutral · 108,247 negative

Leading coverage topics

Cancer Therapeutics coverage across United States · ranked by full-period article count.

Covid 19 Vaccine Development And Efficacy Trials85,803 articles in the full recorded period
8,070 recent · 1,979 prior
Covid 19 Vaccination Campaigns And Rollout Strategies53,669 articles in the full recorded period
5,795 recent · 1,046 prior
Oncology And Targeted Therapy Advancements28,440 articles in the full recorded period
5,253 recent · 7,172 prior
Covid 19 Epidemiology And Transmission Modeling23,314 articles in the full recorded period
3,373 recent · 272 prior
Rare Disease Therapies And Orphan Drugs22,835 articles in the full recorded period
4,860 recent · 6,623 prior
Vaccination Programs And Efficacy Studies20,445 articles in the full recorded period
1,975 recent · 386 prior
Drug Pricing And Reimbursement Strategies19,344 articles in the full recorded period
6,383 recent · 4,703 prior
Gene Therapy And Crispr Technologies19,287 articles in the full recorded period
3,916 recent · 5,313 prior
Booster Doses And Long Term Immunity19,151 articles in the full recorded period
1,437 recent · 313 prior
Covid 19 Hospitalization Rates And Icu Capacity18,889 articles in the full recorded period
2,885 recent · 191 prior

Recent and prior counts use the source comparison windows.

Topics gaining and losing attention

Cancer Therapeutics coverage across United States

KeywordRecentPriorChange
vaccine candidates6,7321,664305%
vaccination campaigns6,1051,192412%
vaccine trials6,0751,651268%
vaccine immunogenicity5,0741,304289%
mass vaccination sites4,501745504%
vaccine decision-making3,854965299%
parental vaccine concerns3,679893312%
anti-vaccination sentiment3,659864323%
vaccine policy controversies3,646593515%
public health orders vaccines3,603555549%
diet prostate cancer7631,351-44%
age prostate cancer8111,351-40%
obesity prostate cancer7541,347-44%
vascetomy prostate cancer7811,328-41%
family history prostate cancer7621,289-41%

Event and signal lenses

Cancer Therapeutics coverage across United States

All complete annual cohorts shown
Falling

Regulatory Risk

243,496 classified articles

vaccine mandate compliance, vaccine policy controversies, vaccine candidates

63.8% critical · 29.9% positive
Rising

Funding Momentum

108,843 classified articles

public health funding, vaccine candidates, vaccine trials

61.2% critical · 43.6% positive
Rising

Growth

109,739 classified articles

earnings report, monetary stance shift, monetary easing

46.8% critical · 45.2% positive

Cancer Therapeutics coverage across United States. Topic labels describe recorded classifications and can include broad context.

RESEARCH SIGNALS

What Cancer Therapeutics research is working on

12,968 papers in the recorded india scope.

Expand panel +
12,968papers
53,351worldwide comparison pool
12,968India-affiliated papers

Research orientation

Promising
5,701
Breakthrough
4,499
Descriptive
1,102
Problem-identifying
981
Cautionary
399
Comparative
197
Critical
89

Contribution mix

Empirical
6,756
Methods-led
3,040
Reviews
2,894
Position pieces
251
Theoretical
27

Tone counts: 12,592 positive · 304 neutral · 72 negative.

Common problems researchers identify
1,070 papers · 8.3% of this field
  • Tumor microenvironment492 papers
  • Immunotherapy491 papers
  • Immune system374 papers
  • Cancer325 papers
  • Cancer immunotherapy224 papers
  • Cancer research174 papers
  • Chimeric antigen receptor89 papers
  • Clinical trial65 papers

Landmark: A framework for advancing our understanding of cancer-associated fibroblasts

Cautions
399 papers · 3.1% of this field
  • Immunotherapy182 papers
  • Immune system152 papers
  • Tumor microenvironment147 papers
  • Cancer research87 papers
  • Cancer85 papers
  • Cancer immunotherapy52 papers
  • Chimeric antigen receptor27 papers
  • T cell26 papers

Landmark: Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

Opportunities
10,200 papers · 78.7% of this field
  • Tumor microenvironment4,695 papers
  • Immune system3,658 papers
  • Cancer research3,231 papers
  • Immunotherapy3,201 papers
  • Cancer1,615 papers
  • Cancer immunotherapy1,319 papers
  • Stromal cell614 papers
  • Cytotoxic T cell598 papers

Landmark: Cancer immunotherapy using checkpoint blockade

Leading institutions

Harvard University
62,927
Dana-Farber Cancer Institute
53,191
The University of Texas MD Anderson Cancer Center
48,648
Memorial Sloan Kettering Cancer Center
41,938
Cornell University
41,214
Brigham and Women's Hospital
36,065

Leading researchers

Jean‐Philippe Coppé
9,599
Jedd D. Wolchok
9,398
Taiwen Li
8,283
Antoni Ribas
7,562
James P. Allison
7,074
Erin Murphy
6,639
Jing Li
6,533
Itay Tirosh
6,108

Highly cited breakthrough-labelled papers

  • Cancer immunotherapy using checkpoint blockade6,497 citations
  • TIMER2.0 for analysis of tumor-infiltrating immune cells5,542 citations
  • The future of immune checkpoint therapy4,710 citations
  • Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor4,030 citations
  • IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade3,763 citations

Common problems researchers identify

1,047 papers · 7 recurring themes
7 cards

Swipe or scroll horizontally to browse.

Tumor Microenvironment / Immune SystemCommon problems researchers identify · 01

Tumor Microenvironment / Immune System

205 papers

19.6% of this theme group

Tumor microenvironment (195) · Immune system (162) · Immunotherapy (121) · Cancer research (43)

Nanoparticle-Mediated Remodeling of the Tumor Microenvironment to Enhance Immunotherapy

The Suppressive Tumor Microenvironment: A Challenge in Cancer Immunotherapy

View research history
YearShare index
2022407.6
2023398.9
2024360.8
2025409.5
Tumor Microenvironment / Cancer ResearchCommon problems researchers identify · 02

Tumor Microenvironment / Cancer Research

196 papers

18.7% of this theme group

Tumor microenvironment (185) · Cancer research (76) · Stromal cell (30) · Metastasis (28)

Therapeutic Targeting of the Tumor Microenvironment

Tumor Microenvironment Complexity: Emerging Roles in Cancer Therapy

View research history
YearShare index
20221003.8
20231083.5
2024855.0
2025938.0
Immunotherapy / Cancer ImmunotherapyCommon problems researchers identify · 03

Immunotherapy / Cancer Immunotherapy

192 papers

18.3% of this theme group

Immunotherapy (178) · Cancer immunotherapy (124) · Cancer (123) · Clinical trial (32)

Imaging of Cancer Immunotherapy: Current Approaches and Future Directions

Development of immune checkpoint therapy for cancer

View research history
YearShare index
20225211.4
20235941.3
20245608.4
20254863.9
Cancer / Cancer ResearchCommon problems researchers identify · 04

Cancer / Cancer Research

159 papers

15.2% of this theme group

Cancer (62) · Cancer research (37) · Metastasis (18) · Cancer cell (14)

Cancer Nanotheranostics: Improving Imaging and Therapy by Targeted Delivery Across Biological Barriers

Organotropism: new insights into molecular mechanisms of breast cancer metastasis

View research history
YearShare index
20225162.2
20235886.7
20245570.3
20254835.7
Immune System / Cytotoxic T CellCommon problems researchers identify · 05

Immune System / Cytotoxic T Cell

124 papers

11.8% of this theme group

Immune system (73) · Cytotoxic T cell (14) · Immunotherapy (47) · Cancer research (28)

CTLs heterogeneity and plasticity: implications for cancer immunotherapy

Optimizing CD8+ T cell-based immunotherapy via metabolic interventions: a comprehensive review of intrinsic and extrinsic modulators

View research history
YearShare index
2022200.5
2023225.1
2024145.7
2025158.3
Immunotherapy / Immune CheckpointCommon problems researchers identify · 06

Immunotherapy / Immune Checkpoint

89 papers

8.5% of this theme group

Immunotherapy (77) · Immune checkpoint (29) · Immune system (46) · Pembrolizumab (9)

Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer

Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors

View research history
YearShare index
2022196.5
2023190.8
2024178.0
2025184.9
Chimeric Antigen Receptor / Cell TherapyCommon problems researchers identify · 07

Chimeric Antigen Receptor / Cell Therapy

82 papers

7.8% of this theme group

Chimeric antigen receptor (81) · Cell therapy (15) · Immunotherapy (55) · T cell (16)

CAR T cell immunotherapy for human cancer

Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward

View research history
YearShare index
2022366.0
2023413.1
2024292.5
2025280.9

Cautions

388 papers · 7 recurring themes
7 cards

Swipe or scroll horizontally to browse.

Immunotherapy / CancerCautions · 01

Immunotherapy / Cancer

95 papers

24.5% of this theme group

Immunotherapy (80) · Cancer (51) · Cancer immunotherapy (39) · Oncology (16)

Advances and challenges in immunotherapy in head and neck cancer

Harnessing nanoprodrugs to enhance cancer immunotherapy: overcoming barriers to precision treatment

View research history
YearShare index
20225303.2
20236080.5
20245745.0
20254891.5
T Cell / Cytotoxic T CellCautions · 02

T Cell / Cytotoxic T Cell

74 papers

19.1% of this theme group

T cell (18) · Cytotoxic T cell (15) · Immune system (35) · Antigen (12)

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti–PD-1 in head and neck cancer

View research history
YearShare index
2022558.6
2023620.1
2024446.6
2025440.0
Tumor Microenvironment / Immune SystemCautions · 03

Tumor Microenvironment / Immune System

74 papers

19.1% of this theme group

Tumor microenvironment (59) · Immune system (53) · Immunotherapy (34) · Cancer research (24)

Plant-derived immunomodulators in cancer: Balancing immune activation and suppression within the tumor microenvironment

Towards the tumor microenvironment scoring methods for immune checkpoint inhibitor response

View research history
YearShare index
2022407.6
2023398.9
2024360.8
2025409.5
Tumor Microenvironment / Stromal CellCautions · 04

Tumor Microenvironment / Stromal Cell

52 papers

13.4% of this theme group

Tumor microenvironment (39) · Stromal cell (10) · Cancer research (21) · Stroma (5)

Stem cell-associated heterogeneity in Glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment

Tumor microenvironment remodeling across thyroid cancer differentiation states revealed by spatial transcriptomics

View research history
YearShare index
2022483.7
2023489.5
2024420.1
2025468.2
Breast Cancer / Tumor MicroenvironmentCautions · 05

Breast Cancer / Tumor Microenvironment

47 papers

12.1% of this theme group

Breast cancer (8) · Tumor microenvironment (21) · Immune system (19) · Glioblastoma (5)

Chronic compression induces transcriptional, metabolic, and functional state changes in macrophages that recapitulate tumor-associated pheno

Chronic compression drives macrophages toward a pathological pro-tumor state

View research history
YearShare index
20221620.7
20231846.4
20241731.8
20251850.1
Chimeric Antigen Receptor / Cell TherapyCautions · 06

Chimeric Antigen Receptor / Cell Therapy

25 papers

6.4% of this theme group

Chimeric antigen receptor (24) · Cell therapy (5) · Immunotherapy (16) · Venetoclax (2)

Evolving CAR-T-Cell Therapy for Cancer Treatment: From Scientific Discovery to Cures

CAR-T cells in solid tumors: Challenges and breakthroughs

View research history
YearShare index
202292.6
2023104.1
202492.7
202596.5
Pembrolizumab / NivolumabCautions · 07

Pembrolizumab / Nivolumab

21 papers

5.4% of this theme group

Pembrolizumab (7) · Nivolumab (6) · Durvalumab (4) · Ipilimumab (4)

Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies

Cost-Effectiveness Analysis of Durvalumab in Limited-Stage Small Cell Lung Cancer in the United States

View research history
YearShare index
2022135.9
2023145.6
2024139.7
2025120.9

Opportunities

9,894 papers · 7 recurring themes
7 cards

Swipe or scroll horizontally to browse.

Tumor Microenvironment / Immune SystemOpportunities · 01

Tumor Microenvironment / Immune System

1,106 papers

18.4% of this theme group

Tumor microenvironment (987) · Immune system (851) · Cancer research (410) · Immunotherapy (324)

Immune targets in the tumor microenvironment treated by radiotherapy

Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy

View research history
YearShare index
2022407.6
2023398.9
2024360.8
2025409.5
Tumor Microenvironment / Cancer ResearchOpportunities · 02

Tumor Microenvironment / Cancer Research

1,082 papers

18.0% of this theme group

Tumor microenvironment (991) · Cancer research (525) · Cancer (234) · Stromal cell (110)

Tumor microenvironment complexity and therapeutic implications at a glance

Role of tumor microenvironment in cancer progression and therapeutic strategy

View research history
YearShare index
20225328.2
20236046.1
20245700.3
20254950.3
Immune System / ImmunotherapyOpportunities · 03

Immune System / Immunotherapy

1,007 papers

16.8% of this theme group

Immune system (501) · Immunotherapy (425) · Blockade (127) · Cancer research (374)

<scp>PD</scp>‐1 as a potential target in cancer therapy

Reversing T-cell Exhaustion in Cancer: Lessons Learned from PD-1/PD-L1 Immune Checkpoint Blockade

View research history
YearShare index
202242.8
202372.3
202447.5
202552.7
Cancer Research / Stromal CellOpportunities · 04

Cancer Research / Stromal Cell

939 papers

15.7% of this theme group

Cancer research (348) · Stromal cell (146) · Metastasis (125) · Extracellular matrix (78)

A peek into cancer-associated fibroblasts: origins, functions and translational impact

Tumor–Stroma Interaction: Revealing Fibroblast-Secreted Exosomes as Potent Regulators of Wnt-Planar Cell Polarity Signaling in Cancer Metast

View research history
YearShare index
2022749.0
2023832.0
2024609.8
2025661.9
Immunotherapy / Cancer ImmunotherapyOpportunities · 05

Immunotherapy / Cancer Immunotherapy

799 papers

13.3% of this theme group

Immunotherapy (652) · Cancer immunotherapy (406) · Cancer (339) · Immune system (356)

Immunotherapy targeting different immune compartments in combination with radiation therapy induces regression of resistant tumors

Development of nano-immunotherapy for cancer treatment: achievements and scopes

View research history
YearShare index
20225161.6
20235903.1
20245564.0
20254767.2
Cytotoxic T Cell / Chimeric Antigen ReceptorOpportunities · 06

Cytotoxic T Cell / Chimeric Antigen Receptor

678 papers

11.3% of this theme group

Cytotoxic T cell (235) · Chimeric antigen receptor (183) · T cell (210) · Immunotherapy (312)

CAR-NK cells: A promising cellular immunotherapy for cancer

Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System

View research history
YearShare index
2022462.1
2023519.4
2024366.4
2025362.6
Nanocarriers / Photothermal TherapyOpportunities · 07

Nanocarriers / Photothermal Therapy

389 papers

6.5% of this theme group

Nanocarriers (34) · Photothermal therapy (35) · Photodynamic therapy (33) · Immunotherapy (154)

Nanoparticle‐Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy

Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy

View research history
YearShare index
202286.1
202372.6
202486.1
202597.5

How this field compares with the research baseline

Orientation shares compared with 25,000 papers in the reference sample.

Research orientationThis fieldReference sample
Promising44.0%37.6%
Breakthrough34.7%25.9%
Descriptive8.5%17.4%
Problem-identifying7.6%9.9%
Cautionary3.1%4.5%
Comparative1.5%3.9%
Critical0.7%0.9%

Concerns receiving less research attention

Counts and shares refer to the stated research pool. A low count describes how much of that research is recorded here, not the absence of a real-world concern.

Concern / example paperPapersShareRaised as a problemWorldwide share
Privacy & surveillanceResistance Mechanisms to Anti-PD Cancer Immunotherapy1281.02%24 (18.8%)0.73%
Energy & datacenter footprint00.0%0 (%)0.0%
Water use00.0%0 (%)0.0%
Carbon & emissions of compute00.0%0 (%)0.0%
Hardware, e-waste & supply chain00.0%0 (%)0.0%
Labour & data work00.0%0 (%)0.0%
Safety & misuse00.0%0 (%)0.0%
Bias & fairness00.0%0 (%)0.01%
Concentration of compute power00.0%0 (%)0.0%

Institution and researcher rankings use citations to their covered work. Research scope: United States. This may be broader than the company geography.

DEMAND, SUPPLY & PLACE

Where demand signals run ahead of mapped supply — the United States

Compare demand signals in the United States’s newsflow with the cancer therapeutics categories mapped to each signal.

Expand panel +
HOW TO READ THE GAP

Signal percentile − supply percentile = gap in percentile points. Positive gaps highlight questions to investigate. A high signal can reflect spending pressure or access friction, as well as potential demand.

The comparison is relative to the signal families on this page. A supply percentile of zero means the lowest relative reading, not zero companies. It is a prioritisation clue, not measured market size or unmet demand.

COMPARISON PERIOD2025-07-01 to 2026-07-01Against 2024-07-01 to 2025-07-01Explore the signals ↓

The opportunity, in one view

Signal and mapped-supply percentiles, their gap, and change in the signal’s article share.

Swipe horizontally to compare all columns →

8 the United States demand signals compared with mapped cancer therapeutics supply
Signal familySignal percentileSupply percentileRelative gapGap (points)Signal share vs prior year
Layoffs & income shocks ↗Spending Pressure85.70.0+85.7+57.7%
Diabetes, hypertension & cardiac burden ↗Disease Burden21.450.0-28.6+21.4%
Cancer burden ↗Disease Burden35.7100.0-64.3+2.5%
Air pollution ↗Environmental Driver21.4—No matching category—-18.3%
Mental health ↗Disease Burden78.6—No matching category—+63.1%
Infectious outbreaks ↗Disease Burden35.7—No matching category—+45.9%
Ageing & elder care ↗Disease Burden28.6—No matching category—-43.4%
Maternal & child health ↗Disease Burden92.9—No matching category—+110.1%

Showing all 8 signals. Select a family for its history and mapped categories.

Where the signals are loudest

All 12 city readings for these demand families in the comparison geography. the United States is highlighted.

Mentions per 10,000 articles

Each city’s reading is a share of its own coverage.

Kentucky172.3

Maternal & child health · Mental health · Layoffs & income shocks

Delaware159.7

Maternal & child health · Ageing & elder care · Cancer burden

Indiana137.6

Maternal & child health · Mental health · Layoffs & income shocks

Maryland130.4

Maternal & child health · Mental health · Layoffs & income shocks

Connecticut124.9

Mental health · Maternal & child health · Ageing & elder care

South Carolina124.2

Maternal & child health · Layoffs & income shocks · Infectious outbreaks

Iowa121.1

Maternal & child health · Layoffs & income shocks · Mental health

Colorado120.9

Mental health · Maternal & child health · Air pollution

Wisconsin120.9

Maternal & child health · Mental health · Ageing & elder care

Louisiana120.9

Maternal & child health · Mental health · Layoffs & income shocks

Tennessee116.2

Layoffs & income shocks · Maternal & child health · Mental health

North Carolina114.7

Mental health · Maternal & child health · Layoffs & income shocks

Inside the leading signals

Open any signal for its quarterly history
SPENDING PRESSURELayoffs & income shocks+85.7percentile-point gap
THE OPERATING HYPOTHESIS

Layoff cycles can pull discretionary spend back toward value offerings.

24.69mentions per 10,000 articles+57.7%share change vs prior year

Mapped cancer therapeutics categories

  • Biopharmaceuticals908

Companies can appear in multiple categories; these counts are not a unique-company total.

Quarterly share of the United States coverage

Mentions per 10,000 articles · zero baseline

091827362024Q3: 152024Q32024Q4: 142024Q42025Q1: 132025Q12025Q2: 192025Q22025Q3: 242025Q32025Q4: 312025Q42026Q1: 192026Q12026Q2: 242026Q2
View quarterly signal counts
Layoffs & income shocks in the United States coverage
QuarterMentionsPer 10,000 articles
2024Q3269215.79
2024Q4265714.98
2025Q1345713.81
2025Q2305519.17
2025Q3668724.54
2025Q4376131.16
2026Q1284319.69
2026Q2188524.49

Where this signal concentrates in the comparison geography

Tennessee44.9 / 10,000
Arkansas41.1 / 10,000
Iowa26.8 / 10,000
DISEASE BURDENDiabetes, hypertension & cardiac burden-28.6percentile-point gap
THE OPERATING HYPOTHESIS

Chronic cardiometabolic burden can turn into decades of management demand per patient.

4.5mentions per 10,000 articles+21.4%share change vs prior year

Mapped cancer therapeutics categories

  • Biopharmaceuticals908
  • Medical Devices96

Companies can appear in multiple categories; these counts are not a unique-company total.

Quarterly share of the United States coverage

Mentions per 10,000 articles · zero baseline

024682024Q3: 32024Q32024Q4: 32024Q42025Q1: 42025Q12025Q2: 42025Q22025Q3: 32025Q32025Q4: 62025Q42026Q1: 42026Q12026Q2: 52026Q2
View quarterly signal counts
Diabetes, hypertension & cardiac burden in the United States coverage
QuarterMentionsPer 10,000 articles
2024Q35553.26
2024Q45393.04
2025Q110174.06
2025Q26934.35
2025Q39083.33
2025Q48056.67
2026Q16374.41
2026Q24135.36

Where this signal concentrates in the comparison geography

Connecticut11.1 / 10,000
Missouri8.4 / 10,000
Mississippi7.2 / 10,000
DISEASE BURDENCancer burden-64.3percentile-point gap
THE OPERATING HYPOTHESIS

Cancer burden can pull screening, diagnostics and oncology capacity demand.

7.52mentions per 10,000 articles+2.5%share change vs prior year

Mapped cancer therapeutics categories

  • Life Sciences1,018
  • Biopharmaceuticals908

Companies can appear in multiple categories; these counts are not a unique-company total.

Quarterly share of the United States coverage

Mentions per 10,000 articles · zero baseline

0369122024Q3: 62024Q32024Q4: 82024Q42025Q1: 62025Q12025Q2: 82025Q22025Q3: 62025Q32025Q4: 102025Q42026Q1: 72026Q12026Q2: 82026Q2
View quarterly signal counts
Cancer burden in the United States coverage
QuarterMentionsPer 10,000 articles
2024Q310876.38
2024Q415518.75
2025Q116166.46
2025Q213068.19
2025Q316466.04
2025Q4123810.26
2026Q111147.72
2026Q26248.11

Where this signal concentrates in the comparison geography

Delaware15.3 / 10,000
Missouri14.4 / 10,000
Maryland12.9 / 10,000
ENVIRONMENTAL DRIVERAir pollution—supply not mapped
THE OPERATING HYPOTHESIS

Sustained air-quality stress can pull respiratory and cardiac care demand with it.

6.47mentions per 10,000 articles-18.3%share change vs prior year

Mapped cancer therapeutics categories

This signal has no matching category in the page’s cancer therapeutics market map, so no supply percentile or gap is assigned.

Quarterly share of the United States coverage

Mentions per 10,000 articles · zero baseline

0369112024Q3: 62024Q32024Q4: 82024Q42025Q1: 72025Q12025Q2: 92025Q22025Q3: 52025Q32025Q4: 52025Q42026Q1: 72026Q12026Q2: 82026Q2
View quarterly signal counts
Air pollution in the United States coverage
QuarterMentionsPer 10,000 articles
2024Q310756.31
2024Q414458.15
2025Q119067.62
2025Q215729.86
2025Q316265.97
2025Q46465.35
2026Q110767.45
2026Q26278.14

Where this signal concentrates in the comparison geography

Louisiana16.4 / 10,000
Delaware14.5 / 10,000
Colorado14.5 / 10,000
DISEASE BURDENMental health—supply not mapped
THE OPERATING HYPOTHESIS

Mental-health pressure can pull counselling and tele-psychiatry demand where it surfaces.

14.86mentions per 10,000 articles+63.1%share change vs prior year

Mapped cancer therapeutics categories

This signal has no matching category in the page’s cancer therapeutics market map, so no supply percentile or gap is assigned.

Quarterly share of the United States coverage

Mentions per 10,000 articles · zero baseline

05914192024Q3: 92024Q32024Q4: 102024Q42025Q1: 72025Q12025Q2: 92025Q22025Q3: 162025Q32025Q4: 122025Q42026Q1: 152026Q12026Q2: 122026Q2
View quarterly signal counts
Mental health in the United States coverage
QuarterMentionsPer 10,000 articles
2024Q316879.9
2024Q4183210.33
2025Q119197.67
2025Q214649.19
2025Q3438416.09
2025Q4152112.6
2026Q1229315.88
2026Q293512.15

Where this signal concentrates in the comparison geography

Colorado42.7 / 10,000
Mississippi32.6 / 10,000
Connecticut29.9 / 10,000
DISEASE BURDENInfectious outbreaks—supply not mapped
THE OPERATING HYPOTHESIS

Outbreak pressure can pull testing, surveillance and rapid-care demand at short notice.

6.38mentions per 10,000 articles+45.9%share change vs prior year

Mapped cancer therapeutics categories

This signal has no matching category in the page’s cancer therapeutics market map, so no supply percentile or gap is assigned.

Quarterly share of the United States coverage

Mentions per 10,000 articles · zero baseline

0368112024Q3: 32024Q32024Q4: 42024Q42025Q1: 32025Q12025Q2: 52025Q22025Q3: 92025Q32025Q4: 32025Q42026Q1: 32026Q12026Q2: 42026Q2
View quarterly signal counts
Infectious outbreaks in the United States coverage
QuarterMentionsPer 10,000 articles
2024Q36733.95
2024Q48004.51
2025Q19813.92
2025Q28605.4
2025Q326509.72
2025Q44653.85
2026Q14403.05
2026Q23684.78

Where this signal concentrates in the comparison geography

Kentucky19.4 / 10,000
South Carolina14.6 / 10,000
Louisiana14.3 / 10,000
DISEASE BURDENAgeing & elder care—supply not mapped
THE OPERATING HYPOTHESIS

An ageing base can shift demand toward geriatric, home and chronic care.

7.85mentions per 10,000 articles-43.4%share change vs prior year

Mapped cancer therapeutics categories

This signal has no matching category in the page’s cancer therapeutics market map, so no supply percentile or gap is assigned.

Quarterly share of the United States coverage

Mentions per 10,000 articles · zero baseline

051015202024Q3: 122024Q32024Q4: 172024Q42025Q1: 122025Q12025Q2: 132025Q22025Q3: 62025Q32025Q4: 82025Q42026Q1: 82026Q12026Q2: 82026Q2
View quarterly signal counts
Ageing & elder care in the United States coverage
QuarterMentionsPer 10,000 articles
2024Q3209212.27
2024Q4302717.07
2025Q1316612.65
2025Q2222213.94
2025Q318016.61
2025Q410428.63
2026Q112948.96
2026Q26898.95

Where this signal concentrates in the comparison geography

Delaware24.3 / 10,000
Connecticut23.5 / 10,000
Indiana16.4 / 10,000
DISEASE BURDENMaternal & child health—supply not mapped
THE OPERATING HYPOTHESIS

Maternal and child burden can pull immunisation, nutrition and pediatric care demand.

18.23mentions per 10,000 articles+110.1%share change vs prior year

Mapped cancer therapeutics categories

This signal has no matching category in the page’s cancer therapeutics market map, so no supply percentile or gap is assigned.

Quarterly share of the United States coverage

Mentions per 10,000 articles · zero baseline

081725342024Q3: 72024Q32024Q4: 72024Q42025Q1: 72025Q12025Q2: 112025Q22025Q3: 292025Q32025Q4: 92025Q42026Q1: 72026Q12026Q2: 112026Q2
View quarterly signal counts
Maternal & child health in the United States coverage
QuarterMentionsPer 10,000 articles
2024Q313337.82
2024Q414147.97
2025Q119627.84
2025Q2186411.69
2025Q3800929.39
2025Q411689.68
2026Q111097.68
2026Q291911.94

Where this signal concentrates in the comparison geography

Delaware62.8 / 10,000
Kentucky61.4 / 10,000
South Carolina60.0 / 10,000
RESEARCH & CHANGING CONVERSATIONS

Related research and changing coverage

the United States cancer therapeutics coverage

Expand panel +
RESEARCH CONTEXT · 2017

2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Hypertension

7,315 citations in the snapshot

RESEARCH CONTEXT · 2019

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Circulation

6,114 citations in the snapshot

RESEARCH CONTEXT · 2019

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Circulation

4,494 citations in the snapshot

RESEARCH CONTEXT · 2019

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Circulation

4,422 citations in the snapshot

What is growing in this coverage

the United States coverage of this page's demand families

KeywordRecent articlesPrior articlesShare change
post-covid complications1,1031051194.7%
last-mile vaccine delivery14523677.0%
epidemic death tolls31353627.8%
snow rescue19936581.3%
disease outbreak deaths700152467.6%
contagion mortality rates22049453.3%

Share changes describe coverage in the stated comparison periods, not search demand or market size.

GEOGRAPHIC FOOTPRINT

Where companies are based

Company counts, hiring and disclosed funding across the recorded hubs.

Expand panel +
8 cards

Swipe or scroll horizontally to browse.

UNDERSTAND THE LANDSCAPE

Cancer Therapeutics in the United States: key questions

Clear definitions for making better comparisons.

What does this landscape measure?

It measures the tracked company ecosystem, recorded funding, hiring and other available evidence. It is not a market-size estimate.

Can segment counts be added together?

No. A company can belong to several segments, so segment counts and funding can overlap.

What does a missing figure mean?

A dash or unavailable panel means the current reviewed source snapshot does not support that figure.

KEEP EXPLORING

Put the United States in context

All landscapes ↗

Company ecosystem snapshot: 31 August 2026. Funding is recorded in USD; filed accounts retain their stated currency and reporting basis. Each section identifies its own coverage. The news and research behind these sections is explorable in Prism.

Canonical landscape ↗
Coming soon